IOSULAMIDE MEGLUMINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H28I6N4O10S.C7H17NO5
Molecular Weight	1569.248
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(=O)CCS(=O)(=O)CCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(N(CC)C(C)=O)=C2I)=C1I

InChI

InChIKey=IRYYCWRQWAKJMU-WZTVWXICSA-N

InChI=1S/C28H28I6N4O10S.C7H17NO5/c1-5-37(11(3)39)25-19(31)15(27(43)44)17(29)23(21(25)33)35-13(41)7-9-49(47,48)10-8-14(42)36-24-18(30)16(28(45)46)20(32)26(22(24)34)38(6-2)12(4)40;1-8-2-4(10)6(12)7(13)5(11)3-9/h5-10H2,1-4H3,(H,35,41)(H,36,42)(H,43,44)(H,45,46);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula	C28H28I6N4O10S
Molecular Weight	1374.035
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C7H17NO5
Molecular Weight	195.2136
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7076433 | https://www.ncbi.nlm.nih.gov/pubmed/7203907 | https://www.ncbi.nlm.nih.gov/pubmed/7076441

Iosulamide is triiodobenzoic acid derivative patented by Sterling Drug Inc as an X-ray contrast agent. Iosulamide shows clear advantages in animal tests over meglumine iodipamide. The intravenous toxicity of Iosulamide meglumine is considerably lower than that of iodipamide (Cholografin) in the mouse and rat. Studies of biliary and urinary excretion patterns indicate Iosulamide is rapidly excreted compared to iodipamide, while at the same time providing equal concentrations in bile. More efficient blood to bile clearance rate and a shorter blood half-life for Iosulamide may account for the lower circulating blood levels and rapid total excretion compared to iodipamide. Iosulamide's rapid blood-bile clearance coupled with its extremely low toxicity may allow rapid administration of high doses, affording superior visualization and safety compared to iodipamide.

Originator

Approval Year

PubMed

Title	Date	PubMed
Failure of iosulamide to enhance hepatic tumors in rats.	1982-01-01	7076433

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:39:43 GMT 2025` Edited by `admin` on `Mon Mar 31 19:39:43 GMT 2025`
Record UNII	255T933X5M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOSULAMIDE MEGLUMINE

Official Name

English

3,3'-(SULFONYLBIS(ETHYLENECARBONYLIMINO))BIS(5-(N-ETHYLACETAMINO)-2,4,6-TRIIODOBENZOIC ACID) COMPOUND WITH 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:1)

Preferred Name

English

IOSULAMIDE MEGLUMINE [USAN]

Common Name

English

BENZOIC ACID, 3,3'-(SULFONYLBIS((1-OXO-3,1-PROPANEDIYL)IMINO))BIS(5-(ACETYLETHYLAMINO)-2,4,6-TRIIODO-, COMPD. WITH 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:1)

Common Name

English

Code System Code Type Description

ChEMBL

CHEMBL1615440